Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Evaluation of the Safety and Efficacy of CLONICEL (Clonidine HCl Sustained Release) as Add-on to Psychostimulant Medication vs. Psychostimulant Medication Alone in Children and Adolescents With ADHD

NCT00641329 is registered in ClinicalTrials.gov with Addrenex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00641329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00641329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Evaluation of the Safety and Efficacy of CLONICEL (Clonidine HCl Sustained Release) as Add-on to Psychostimulant Medication vs. Psychostimulant Medication Alone in Children and Adolescents With ADHD
Lead sponsor
Addrenex Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2008
Completion date
February 28, 2009
Enrollment
198 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

adhd